Novartis Oncology Company Profile

01:33 EST 21st November 2017 | BioPortfolio

News Articles [1359 Associated News Articles listed on BioPortfolio]

Novartis bolsters oncology offering with $3.9bn deal

Novartis has unveiled plans to buy Advanced Accelerator Applications (AAA) for $3.9 billion in cash, beefing up its oncology portfolio.

Novartis Plans $3.9B Acquisition Of Advanced Accelerator Applications

NewsNovartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio. The transaction would bolster Novartis' oncology presence with both near-term prod...

Novartis to acquire Advanced Accelerator Applications for oncology portfolio

Novartis has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to ...

Axel Hoos, GSK: Focusing on immuno-oncology and cancer epigenetics

GSK has had a recent change in Oncology after recently divesting their marketed oncology products to Novartis whilst retaining their R&D pipeline. During BIO 2015, Axel Hoos, VP Oncology R&D at GSK ex...

Novartis to bolster oncology portfolio with $3.9 billion acquisition

Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce its oncology portfolio. The deal translates to $41 per share,...

Novartis Oncology plans acceleration of Russian expansion

Swiss pharma giant Novartis is considering accelerating expansion in the Russian market of anti-cancer…

Novartis to Expand Oncology Business by Acquiring Advanced Accelerator Applications for $3.9 Billion

Basel, October 30, 2017 – Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a ten...

Novartis to buy nuclear medicine firm Advanced Accelerator Applications for $3.9bn

Novartis has agreed to acquire French radiopharmaceutical company Advanced Accelerator Applications (AAA) for $3.9bn to strengthen its oncology presence.

Clinical Trials [500 Associated Clinical Trials listed on BioPortfolio]

Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.

The purpose of this study is to collect and assess long-term safety of everolimus in patients who are currently receiving everolimus treatment in a Novartis-sponsored, Oncology CD&MA study...

Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative

Countries throughout the world are facing a growing non-communicable disease (NCD) burden. In developing countries, medicines to treat NCDs are often difficult to access or too expensive f...

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to 72 Months) Versus Control Vaccines

This study will evaluate the safety, tolerability and immunogenicity of one or two 0.25mL or 0.5mL intramuscular injections of influenza vaccine compared with control vaccine in subjects 6...

Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study

The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, ...

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

This study is aimed to evaluate safety, tolerabilty and immunogenicity of three doses of Novartis Meningococcal B vaccine and of one dose of Novartis Menongococcal ACWY vaccine when adnmi...

Companies [770 Associated Companies listed on BioPortfolio]

Novartis Oncology

Novartis Consumer Health

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innova...

Novartis Pharmaceuticals Corporation (NPC), a US subsidiary of Novartis AG

Novartis AG

Novartis's name, derived from the Latin novae artes, means "new skills" and reflects Novartis's commitment to focus research and development to bring new healthcare products to the...

Novartis Vaccines and Diagnostics

Novartis Vaccines is a global leader in providing vaccines to protect against deadly meningococcal disease. Through industry-leading scientific expertise, the company is focused on extending critical ...

More Information about "Novartis Oncology" on BioPortfolio

We have published hundreds of Novartis Oncology news stories on BioPortfolio along with dozens of Novartis Oncology Clinical Trials and PubMed Articles about Novartis Oncology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Novartis Oncology Companies in our database. You can also find out about relevant Novartis Oncology Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record